Abstract

Tie2, coded by the TEK gene, is a tyrosine kinase receptor and plays a central role in vascular stability. It was suggested that variations in the TEK gene might influence the susceptibility to asthma and allergic conjunctivitis. The aim of this study was to further investigate these suggestions, involving different populations and to study the Tie2 related pathway on a mouse model of asthma. The discovery, stage I cohort involved 306 patients with moderate and severe allergic rhinitis, the stage II study consisted of four cohorts, namely, adult and pediatric asthmatics and corresponding controls. Altogether, there were 1,258 unrelated individuals in these cohorts, out of which 63.9% were children and 36.1% were adults. In stage I, 112 SNPs were screened in the TEK gene of the patients in order to search for associations with asthma and allergic conjunctivitis. The top associated SNPs were selected for association studies on the replication cohorts. The rs3824410 SNP was nominally associated with a reduced risk of asthma in the stage I cohort and with severe asthma within the asthmatic population (p=0.009; OR=0.48) in the replication cohort. In the stage I study, 5 SNPs were selected in conjunctivitis. Due to the low number of adult patients with conjunctivitis, only children were involved in stage II. Within the asthmatic children, the rs622232 SNP was associated with conjunctivitis in boys in the dominant model (p=0.004; OR=4.76), while the rs7034505 showed association to conjunctivitis in girls (p=0.012; OR=2.42). In the lung of a mouse model of asthma, expression changes of 10 Tie2 pathway-related genes were evaluated at three points in time. Eighty percent of the selected genes showed significant changes in their expressions at least at one time point during the process, leading from sensitization to allergic airway inflammation. The expressions of both the Tek gene and its ligands showed a reduced level at all time points. In conclusion, our results provide additional proof that the Tie2 pathway, the TEK gene and its variations might have a role in asthma and allergic conjunctivitis. The gene and its associated pathways can be potential therapeutic targets in both diseases.

Highlights

  • Tie2 is a tyrosine-protein kinase receptor located principally on vascular endothelial cells and plays a crucial role in the stability of the vascular system (Zhang et al, 2019)

  • We investigated whether genetic variations in the TEK gene influence the susceptibility to asthma or allergic conjunctivitis in multiple populations

  • We studied the possible role of Tie2 related pathways on a mouse model of asthma

Read more

Summary

Introduction

Tie is a tyrosine-protein kinase receptor located principally on vascular endothelial cells and plays a crucial role in the stability of the vascular system (Zhang et al, 2019). In human there are three known Tie ligands, angiopoietin 1 (Ang1), Ang, and Ang with similar affinity for binding to Tie. The best-studied member, Ang stimulates the activity of the kinase by binding to Tie. The role of Ang is rather controversial, it can function as an Ang antagonist, in some cases, it may act as a partial agonist. Ang can modulate Ang signaling and has an antimicrobial effect. Tie signaling pathway appears to complement the VEGF pathway by contributing to subsequent stages of vascular development (Brindle et al, 2006; Augustin et al, 2009; Thurston and Daly, 2012)

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.